4-(2,4-diaminopteridin-6-yl)phenol | 677297-67-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 蝶啶及其衍生物
• 英文名称: 4-(2,4-diaminopteridin-6-yl)phenol
• 英文别名: Phenol, 4-(2,4-diamino-6-pteridinyl)-
• CAS: 677297-67-5
• 化学式: C₁₂H₁₀N₆O
• 分子量: 254.251
• InChiKey: FUTZONJYAAOCTH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  124
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  4-羟基-alpha-氧代苯乙醛 、 2,4,5,6-四氨基嘧啶硫酸盐 在 盐酸羟胺 作用下， 以 甲醇 为溶剂， 反应 3.25h， 以50%的产率得到4-(2,4-diaminopteridin-6-yl)phenol
  参考文献：
  名称：

  Discovery of 3,3‘-(2,4-Diaminopteridine-6,7-diyl)diphenol as an Isozyme-Selective Inhibitor of PI3K for the Treatment of Ischemia Reperfusion Injury Associated with Myocardial Infarction

  摘要：

  In studies aimed toward identifying effective and safe inhibitors of kinase signaling cascades that underlie ischemia/reperfusion (I/R) injury, we synthesized a series of pteridines and pyridopyrazines. The design strategy was inspired by the examination of naturally occurring PI3K inhibitors such as wortmannin and quercetin, and building a pharmacophore-based model used for optimization. Structural modifications led to hybrid molecules which incorporated aminopyrimidine and aminopyridine moieties with ATP mimetic characteristics into the pharmacophore motifs to modulate kinase affinity and selectivity. Elaborations involving substitutions of the 2 and 4 positions of the pyrimidine or pyridine ring and the 6 and 7 positions of the central pyrazine ring resulted in in vivo activity profiles which identified potent inhibitors of vascular endothelial growth factor (VEGF) induced vascular leakage. Pathway analysis identified a diaminopteridine-diphenol as a potent and selective phosphatidylinositol-3-kinase (PI3K) inhibitor. The structure -activity relationship studies of various analogues of diaminopteridine-diphenol-based on biochemical assays resulted in potent inhibitors of PI3K.

  DOI：

  10.1021/jm051056c

文献信息

• Vasculostatic agents and methods of use thereof
  申请人：Wrasidlo Wolfgang

  公开号：US20050282814A1

  公开（公告）日：2005-12-22

  Compositions and methods and are provided for treating disorders associated with compromised vasculostasis. Invention methods and compositions are useful for treating a variety of disorders including for example, stroke, myocardial infarction, cancer, ischemia/reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as retinopathies or macular degeneration or other vitreoretinal diseases, inflammatory diseases, vascular leakage syndrome, edema, transplant rejection, adult/acute respiratory distress syndrome (ARDS), and the like.

  提供了用于治疗与血管稳态受损相关的疾病的组合物和方法。发明的方法和组合物可用于治疗各种疾病，包括中风、心肌梗死、癌症、缺血/再灌注损伤、类风湿性关节炎等自身免疫疾病、眼部疾病如视网膜病变或黄斑变性或其他玻璃体视网膜疾病、炎症性疾病、血管渗漏综合征、水肿、移植排斥反应、成人/急性呼吸窘迫综合征（ARDS）等。
• Kinase inhibitors and methods of use thereof
  申请人：Doukas John

  公开号：US20070259876A1

  公开（公告）日：2007-11-08

  Compositions and methods and are provided for treating disorders associated with compromised vasculostasis. Invention methods and compositions are useful for treating a variety of disorders including for example, stroke, myocardial infarction, cancer, ischemia/reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as uveitis, retinopathies or macular degeneration, macular edema or other vitreoretinal diseases, inflammatory diseases such as autoimmune diseases, vascular leakage syndrome, edema, or diseases involving leukocyte activation, transplant rejection, respiratory diseases such as asthma, adult or acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease, and the like.

  提供了用于治疗与血管稳态受损相关的疾病的组合物和方法。发明方法和组合物可用于治疗多种疾病，包括中风、心肌梗死、癌症、缺血/再灌注损伤、类风湿关节炎等自身免疫疾病、眼部疾病如葡萄膜炎、视网膜病变或黄斑变性、黄斑水肿或其他玻璃体视网膜疾病、自身免疫疾病、血管渗漏综合征、水肿或涉及白细胞活化的疾病、移植排斥反应、呼吸道疾病如哮喘、成人或急性呼吸窘迫综合征（ARDS）、慢性阻塞性肺疾病等。
• VASCULOSTATIC AGENTS AND METHODS OF USE THEREOF
  申请人：Wrasidlo Wolfgang

  公开号：US20100278811A1

  公开（公告）日：2010-11-04

  Compositions and methods and are provided for treating disorders associated with compromised vasculostasis. Invention methods and compositions are useful for treating a variety of disorders including for example, stroke, myocardial infarction, cancer, ischemia/reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as retinopathies or macular degeneration or other vitreoretinal diseases, inflammatory diseases, vascular leakage syndrome, edema, transplant rejection, adult/acute respiratory distress syndrome (ARDS), and the like.

  本发明提供了用于治疗与血管稳态受损相关的疾病的组合物和方法。本发明的方法和组合物可用于治疗各种疾病，例如中风、心肌梗塞、癌症、缺血/再灌注损伤、自身免疫疾病，如类风湿性关节炎、眼部疾病，如视网膜病变或黄斑变性或其他玻璃体视网膜疾病、炎症性疾病、血管渗漏综合症、水肿、移植排斥、成人/急性呼吸窘迫综合症（ARDS）等。
• Vasculostatic Agents and Methods of Use Thereof
  申请人：Wrasidlo Wolfgang

  公开号：US20100330030A1

  公开（公告）日：2010-12-30

  Compositions and methods and are provided for treating disorders associated with compromised vasculostasis. Invention methods and compositions are useful for treating a variety of disorders including for example, stroke, myocardial infarction, cancer, ischemia/reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as retinopathies or macular degeneration or other vitreoretinal diseases, inflammatory diseases, vascular leakage syndrome, edema, transplant rejection, adult/acute respiratory distress syndrome (ARDS), and the like.

  提供用于治疗与血管稳定性受损相关的疾病的组合物和方法。发明的方法和组合物可用于治疗多种疾病，包括中风、心肌梗塞、癌症、缺血/再灌注损伤、自身免疫疾病如类风湿性关节炎、眼部疾病如视网膜病变或黄斑变性或其他玻璃体视网膜疾病、炎症性疾病、血管渗漏综合征、水肿、移植排斥、成人/急性呼吸窘迫综合征（ARDS）等。
• EP1549614A4
  申请人：——

  公开号：EP1549614A4

  公开（公告）日：2008-04-16